Renoprotective effects of sodium-glucose cotransporter-2 inhibitors

Kidney International

Volumn 94, Issue 1, 2018, Pages 26-39

  Heerspink, Hiddo J L ^a   Kosiborod, Mikhail ^b   Inzucchi, Silvio E ^c   Cherney, David Z I ^d  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

albuminuria; blood pressure; cardiovascular; diabetic kidney disease; heart failure; inflammation; SGLT2 inhibition

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANAGLIFLOZIN; DAPAGLIFLOZIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DIURETIC AGENT; EMPAGLIFLOZIN; ERTUGLIFLOZIN; EXENDIN 4; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; IPRAGLIFLOZIN; LIRAGLUTIDE; LOOP DIURETIC AGENT; LUSEOGLIFLOZIN; METFORMIN; PHLORIZIN; PLACEBO; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SOTAGLIFLOZIN; SULFONYLUREA DERIVATIVE; TOFOGLIFLOZIN; BENZHYDRYL DERIVATIVE; GLUCOSIDE; PROTECTIVE AGENT; SLC5A2 PROTEIN, HUMAN; SODIUM; SODIUM GLUCOSE COTRANSPORTER 2;

ALBUMINURIA; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; BALANITIS; BLOOD PRESSURE; BODY WEIGHT; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY FAILURE; COMBINATION DRUG THERAPY; DIABETIC NEPHROPATHY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; ESTIMATED GLOMERULAR FILTRATION RATE; GLOMERULUS FILTRATION; HEART FAILURE; HEART INFARCTION; HEART PROTECTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; MONOTHERAPY; NATRIURESIS; NEPHROLOGIST; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; RENAL PROTECTION; REVIEW; VAGINA CANDIDIASIS; BLOOD; CLINICAL TRIAL (TOPIC); COMPLICATION; DISEASE EXACERBATION; GLUCOSE BLOOD LEVEL; HOSPITALIZATION; KIDNEY; METABOLISM; MORTALITY; PHARMACOLOGY; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; URINARY EXCRETION; URINE;

BENZHYDRYL COMPOUNDS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; GLUCOSIDES; HOSPITALIZATION; HUMANS; KIDNEY; PROTECTIVE AGENTS; RENAL ELIMINATION; SODIUM; SODIUM-GLUCOSE TRANSPORTER 2; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS; TREATMENT OUTCOME;

EID: 85046816925     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1016/j.kint.2017.12.027     Document Type: Review

References (140)

1. Holman, R.R., Paul, S.K., Bethel, M.A., et al. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med 359 (2008), 1565–1576.
2. Ismail-Beigi, F., Craven, T., Banerji, M.A., et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 376 (2010), 419–430.
3. Gerstein, H.C., Miller, M.E., Genuth, S., et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 364 (2011), 818–828.
4. Wong, M.G., Perkovic, V., Chalmers, J., et al. Long-term benefits of intensive glucose control for preventing end-stage kidney disease: ADVANCE-ON. Diabetes Care 39 (2016), 694–700.
5. Bonadonna, R.C., Borghi, C., Consoli, A., et al. Novel antidiabetic drugs and cardiovascular risk: primum non nocere. Nutr Metab Cardiovasc Dis 26 (2016), 759–766.
6. Cornel, J.H., Bakris, G.L., Stevens, S.R., et al. Effect of sitagliptin on kidney function and respective cardiovascular outcomes in type 2 diabetes: outcomes from TECOS. Diabetes Care 39 (2016), 2304–2310.
7. Groop, P.H., Cooper, M.E., Perkovic, V., et al. Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial. Diabetes Obes Metab 19 (2017), 1610–1619.
8. Lovshin, J.A., Rajasekeran, H., Lytvyn, Y., et al. Dipeptidyl peptidase 4 inhibition stimulates distal tubular natriuresis and increases in circulating SDF-1alpha1-67 in patients with type 2 diabetes. Diabetes Care 40 (2017), 1073–1081.
9. Scirica, B.M., Bhatt, D.L., Braunwald, E., et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369 (2013), 1317–1326.
10. Zannad, F., Cannon, C.P., Cushman, W.C., et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet 385 (2015), 2067–2076.
11. Zinman, B., Wanner, C., Lachin, J.M., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
12. Wanner, C., Inzucchi, S.E., Lachin, J.M., et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375 (2016), 323–334.
13. Neal, B., Perkovic, V., Mahaffey, K.W., et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377 (2017), 644–657.
14. Marso, S.P., Bain, S.C., Consoli, A., et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375 (2016), 1834–1844.
15. Marso, S.P., Daniels, G.H., Brown-Frandsen, K., et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375 (2016), 311–322.
16. Mann, J.F.E., Orsted, D.D., Brown-Frandsen, K., et al. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med 377 (2017), 839–848.
17. Holman, R.R., Bethel, M.A., Mentz, R.J., et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 377 (2017), 1228–1239.
18. Kernan, W.N., Viscoli, C.M., Furie, K.L., et al. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med 374 (2016), 1321–1331.
19. Yaghi, S., Furie, K.L., Viscoli, C.M., et al. Pioglitazone prevents stroke in patients with a recent transient ischemic attack or ischemic stroke: a planned secondary analysis of the IRIS trial (Insulin Resistance Intervention After Stroke). Circulation 137 (2018), 455–463.
20. Young, L.H., Viscoli, C.M., Curtis, J.P., et al. Cardiac outcomes after ischemic stroke or transient ischemic attack: effects of pioglitazone in patients with insulin resistance without diabetes mellitus. Circulation 135 (2017), 1882–1893.
21. DeFronzo, R.A., Hompesch, M., Kasichayanula, S., et al. Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes. Diabetes Care 36 (2013), 3169–3176.
22. Rieg, T., Masuda, T., Gerasimova, M., et al. Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia. Am J Physiol Renal Physiol 306 (2014), F188–F193.
23. Pavy-Le Traon, A., Fontaine, S., Tap, G., et al. Cardiovascular autonomic neuropathy and other complications in type 1 diabetes. Clin Auton Res 20 (2010), 153–160.
24. Ferrannini, G., Hach, T., Crowe, S., et al. Energy balance after sodium-glucose cotransporter 2 inhibition. Diabetes Care 38 (2015), 1730–1735.
25. Inzucchi, S.E., Zinman, B., Fitchett, D., et al. How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis from the EMPA-REG OUTCOME trial. Diabetes Care 41 (2018), 356–363.
26. Monica Reddy, R.P., Inzucchi, S.E., SGLT2 inhibitors in the management of type 2 diabetes. Endocrine 53 (2016), 364–372.
27. Peacock, S.C., Lovshin, J.A., Cherney, D.Z.I., Perioperative considerations for the use of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes. Anesth Analg 126 (2018), 699–704.
28. Cherney, D.Z., Perkins, B.A., Soleymanlou, N., et al. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol, 13, 2014, 28.
29. Cherney, D.Z., Perkins, B.A., Soleymanlou, N., et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 129 (2014), 587–597.
30. Cherney, D.Z., Perkins, B.A., Soleymanlou, N., et al. Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes. Kidney Int 86 (2014), 1057–1058.
31. Perkins, B.A., Cherney, D.Z., Partridge, H., et al. Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial. Diabetes Care 37 (2014), 1480–1483.
32. Perkins, B.A., Cherney, D.Z., Soleymanlou, N., et al. Diurnal glycemic patterns during an 8-week open-label proof-of-concept trial of empagliflozin in type 1 diabetes. PLoS One, 10, 2015, e0141085.
33. Skrtic, M., Yang, G.K., Perkins, B.A., et al. Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration. Diabetologia 57 (2014), 2599–2602.
34. Peters, A.L., Buschur, E.O., Buse, J.B., et al. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care 38 (2015), 1687–1693.
35. Vasilakou, D., Karagiannis, T., Athanasiadou, E., et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 159 (2013), 262–274.
36. Schernthaner, G., Gross, J.L., Rosenstock, J., et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care 36 (2013), 2508–2515.
37. Ridderstrale, M., Andersen, K.R., Zeller, C., et al. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol 2 (2014), 691–700.
38. Cherney, D.Z.I., Cooper, M.E., Tikkanen, I., et al. Pooled analysis of phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin. Kidney Int 93 (2018), 231–244.
39. Inzucchi, S.E., Zinman, B., Wanner, C., et al. SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials. Diab Vasc Dis Res 12 (2015), 90–100.
40. Komoroski, B., Vachharajani, N., Feng, Y., et al. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther 85 (2009), 513–519.
41. Tanaka, H., Takano, K., Iijima, H., et al. Factors affecting canagliflozin-induced transient urine volume increase in patients with type 2 diabetes mellitus. Adv Ther 34 (2017), 436–451.
42. Hirose, S., Nakajima, S., Iwahashi, Y., et al. Impact of the 8-week administration of tofogliflozin for glycemic control and body composition in Japanese patients with type 2 diabetes mellitus. Intern Med 55 (2016), 3239–3245.
43. Lambers Heerspink, H.J., de Zeeuw, D., Wie, L., et al. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab 15 (2013), 853–862.
44. Sano, M., Takei, M., Shiraishi, Y., et al. Increased hematocrit during sodium-glucose cotransporter 2 inhibitor therapy indicates recovery of tubulointerstitial function in diabetic kidneys. J Clin Med Res 8 (2016), 844–847.
45. Shah, S., Khatri, I., Freis, E.D., Mechanism of antihypertensive effect of thiazide diuretics. Am Heart J 95 (1978), 611–618.
46. Heerspink, H.J., Perkins, B.A., Fitchett, D.H., et al. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation 134 (2016), 752–772.
47. Schmieder, R., Ott, C., Linz, P., et al. OS 12-03 SGLT-2-inhibition with dapagliflozin reduces tissue sodium content [ISH 2016 abstract book]. J Hypertens, 34(suppl 1), 2016, e76.
48. Rajasekeran, H., Cherney, D.Z., Lovshin, J.A., Do effects of sodium-glucose cotransporter-2 inhibitors in patients with diabetes give insight into potential use in non-diabetic kidney disease?. Curr Opin Nephrol Hypertens 26 (2017), 358–367.
49. Mazidi, M., Rezaie, P., Gao, H.K., et al. Effect of sodium-glucose cotransport-2 inhibitors on blood pressure in people with type 2 diabetes mellitus: a systematic review and meta-analysis of 43 randomized control trials with 22 528 patients. J Am Heart Assoc, 6(6), 2017 https://doi.org/10.1161/JAHA.116.004007.
50. Kawasoe, S., Maruguchi, Y., Kajiya, S., et al. Mechanism of the blood pressure-lowering effect of sodium-glucose cotransporter 2 inhibitors in obese patients with type 2 diabetes. BMC Pharmacol Toxicol, 18, 2017, 23.
51. Baker, W.L., Buckley, L.F., Kelly, M.S., et al. Effects of sodium-glucose cotransporter 2 inhibitors on 24-hour ambulatory blood pressure: a systematic review and meta-Analysis. J Am Heart Assoc, 6(5), 2017 https://doi.org/10.1161/JAHA.117.005686.
52. Ansary, T.M., Fujisawa, Y., Rahman, A., et al. Responses of renal hemodynamics and tubular functions to acute sodium-glucose cotransporter 2 inhibitor administration in non-diabetic anesthetized rats. Sci Rep, 7, 2017, 9555.
53. Pfeifer, M., Townsend, R.R., Davies, M.J., et al. Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis. Cardiovasc Diabetol, 16, 2017, 29.
54. Kohan, D.E., Fioretto, P., Tang, W., et al. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int 85 (2014), 962–971.
55. Mithal A, Barnett AH, Manassie J, et al. Empagliflozin in patients with type 2 diabetes mellitus (T2DM) and stage 3A, 3B and 4 chronic kidney disease (CKD). Presented at: European Association for the Study of Diabetes (EASD), September 23–27, 2013; Barcelona, Spain.
56. Yale, J.F., Bakris, G., Cariou, B., et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes Metab 16 (2014), 1016–1027.
57. Petrykiv, S., Sjöstrom, C.D., Greasley, P.J., et al. Differential effects of dapagliflozin on cardiovascular risk factors at varying degrees of renal function. Clin J Am Soc Nephrol 12 (2017), 751–759.
58. Perkovic, V., De Zeeuw, D., Mahaffey, K., et al. Canagliflozin and renal outcomes in type 2 diabetes. Data from the Canvas program. J Am Soc Nephrol(supp 1), 2017, B4.
59. Kosiborod, M., Cavender, M.A., Fu, A.Z., et al. Lower risk of heart failure and death in patients initiated on SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study. (Comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors). Circulation 136 (2017), 249–259.
60. Lee, G., Oh, S.W., Hwang, S.S., et al. Comparative effectiveness of oral antidiabetic drugs in preventing cardiovascular mortality and morbidity: a network meta-analysis. PLoS One, 12, 2017, e0177646.
61. Nystrom, T., Bodegard, J., Nathanson, D., et al. Novel oral glucose-lowering drugs are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes. Diabetes Obes Metab 19 (2017), 831–841.
62. Lytvyn, Y., Bjornstad, P., Udell, J.A., et al. Sodium glucose cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials. Circulation 136 (2017), 1643–1658.
63. Perkins, B.A., Udell, J.A., Cherney, D.Z., No need to sugarcoat the message: is cardiovascular risk reduction from SGLT2 inhibition related to natriuresis?. Am J Kidney Dis 68 (2016), 349–352.
64. Skrtic, M., Cherney, D.Z., Sodium-glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy. Curr Opin Nephrol Hypertens 24 (2015), 96–103.
65. Petrykiv, S.I., Laverman, G.D., Zeeuw, D., Heerspink, H.J.L., The albuminuria lowering response to dapagliflozin is variable and reproducible between individual patients. Diabetes Obes Metab 19 (2017), 1363–1370.
66. Cherney, D.Z., Udell, J.A., Use of sodium glucose cotransporter 2 inhibitors in the hands of cardiologists: with great power comes great responsibility. Circulation 134 (2016), 1915–1917.
67. Butler, J., Hamo, C.E., Filippatos, G., et al. The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors. Eur J Heart. Fail 19 (2017), 1390–1400.
68. Januzzi, J.L. Jr., Butler, J., Jarolim, P., et al. Effects of canagliflozin on cardiovascular biomarkers in older adults with type 2 diabetes. J Am Coll Cardiol 70 (2017), 704–712.
69. Fukuda, T., Bouchi, R., Terashima, M., et al. Ipragliflozin reduces epicardial fat accumulation in non-obese type 2 diabetic patients with visceral obesity: a pilot study. Diabetes Ther 8 (2017), 851–861.
70. Xu, L., Nagata, N., Nagashimada, M., et al. SGLT2 inhibition by empagliflozin promotes fat utilization and browning and attenuates inflammation and insulin resistance by polarizing M2 macrophages in diet-induced obese mice. EBioMedicine 20 (2017), 137–149.
71. Ye, Y., Bajaj, M., Yang, H.C., et al. SGLT-2 inhibition with dapagliflozin reduces the activation of the Nlrp3/ASC inflammasome and attenuates the development of diabetic cardiomyopathy in mice with type 2 diabetes. Further augmentation of the effects with saxagliptin, a DPP4 inhibitor. Cardiovasc Drugs Ther 31 (2017), 119–132.
72. Shi, X., Verma, S., Yun, J., et al. Effect of empagliflozin on cardiac biomarkers in a zebrafish model of heart failure: clues to the EMPA-REG OUTCOME trial?. Mol Cell Biochem 433 (2017), 97–102.
73. Lee, T.M., Chang, N.C., Lin, S.Z., Dapagliflozin, a selective SGLT2 inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts. Free Radic Biol Med 104 (2017), 298–310.
74. Muskiet, M.H., van Raalte, D.H., van Bommel, E., et al. Understanding EMPA-REG OUTCOME. Lancet Diabetes Endocrinol 3 (2015), 928–929.
75. Baartscheer, A., Schumacher, C.A., Wust, R.C., et al. Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits. Diabetologia 60 (2017), 568–573.
76. Di Franco, A., Cantini, G., Tani, A., et al. Sodium-dependent glucose transporters (SGLT) in human ischemic heart: a new potential pharmacological target. Int J Cardiol 243 (2017), 86–90.
77. Ferrannini, E., Mark, M., Mayoux, E., CV protection in the EMPA-REG OUTCOME trial: a “thrifty substrate” hypothesis. Diabetes Care 39 (2016), 1108–1114.
78. Mudaliar, S., Alloju, S., Henry, R.R., Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis. Diabetes Care 39 (2016), 1115–1122.
79. Habibi, J., Aroor, A.R., Sowers, J.R., et al. Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes. Cardiovasc Diabetol, 16, 2017, 9.
80. Kawanami, D., Matoba, K., Takeda, Y., et al. SGLT2 inhibitors as a therapeutic option for diabetic nephropathy. Int J Mol Sci, 18(5), 2017 https://doi.org/10.3390/ijms18051083.
81. Terami, N., Ogawa, D., Tachibana, H., et al. Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice. PLoS One, 9, 2014, e100777.
82. Wakisaka, M., Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375 (2016), 1799–1800.
83. Nagata, T., Fukuzawa, T., Takeda, M., et al. Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice. Br J Pharmacol 170 (2013), 519–531.
84. Gembardt, F., Bartaun, C., Jarzebska, N., et al. The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension. Am J Physiol Renal Physiol 307 (2014), F317–F325.
85. Wang, X.X., Levi, J., Luo, Y., et al. SGLT2 expression is increased in human diabetic nephropathy: SGLT2 inhibition decreases renal lipid accumulation, inflammation and the development of nephropathy in diabetic mice. J Biol Chem 292 (2017), 5335–5348.
86. Har, R., Scholey, J.W., Daneman, D., et al. The effect of renal hyperfiltration on urinary inflammatory cytokines/chemokines in patients with uncomplicated type 1 diabetes mellitus. Diabetologia 56 (2013), 1166–1173.
87. Har, R.L., Reich, H.N., Scholey, J.W., et al. The urinary cytokine/chemokine signature of renal hyperfiltration in adolescents with type 1 diabetes. PLoS One, 9, 2014, e111131.
88. Cherney, D.Z., Konvalinka, A., Zinman, B., et al. Effect of protein kinase Cbeta inhibition on renal hemodynamic function and urinary biomarkers in humans with type 1 diabetes: a pilot study. Diabetes Care 32 (2009), 91–93.
89. Cherney, D.Z., Reich, H.N., Scholey, J.W., et al. The effect of aliskiren on urinary cytokine/chemokine responses to clamped hyperglycaemia in type 1 diabetes. Diabetologia 56 (2013), 2308–2317.
90. Cherney, D.Z., Scholey, J.W., Daneman, D., et al. Urinary markers of renal inflammation in adolescents with Type 1 diabetes mellitus and normoalbuminuria. Diabet Med 29 (2012), 1297–1302.
91. Cherney, D.Z., Scholey, J.W., Sochett, E., et al. The acute effect of clamped hyperglycemia on the urinary excretion of inflammatory cytokines/chemokines in uncomplicated type 1 diabetes: a pilot study. Diabetes Care 34 (2011), 177–180.
92. Edwards, A., Castrop, H., Laghmani, K., et al. Effects of NKCC2 isoform regulation on NaCl transport in thick ascending limb and macula densa: a modeling study. Am J Physiol Renal Physiol 307 (2014), F137–F146.
93. Coughlan, M.T., Nguyen, T.V., Penfold, S.A., et al. Mapping time-course mitochondrial adaptations in the kidney in experimental diabetes. Clin Sci (Lond) 130 (2016), 711–720.
94. O'Neill, J., Fasching, A., Pihl, L., et al. Acute SGLT inhibition normalizes O2 tension in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic rats. Am J Physiol Renal Physiol 309 (2015), F227–F234.
95. Chang, Y.K., Choi, H., Jeong, J.Y., et al. Dapagliflozin, SGLT2 inhibitor, attenuates renal ischemia-reperfusion injury. PLoS One, 11, 2016, e0158810.
96. Cherney, D.Z., Perkins, B.A., Sodium-glucose cotransporter 2 inhibition in type 1 diabetes: simultaneous glucose lowering and renal protection?. Can J Diabetes 38 (2014), 356–363.
97. Norton, L., Shannon, C.E., Fourcaudot, M., et al. Sodium-glucose co-transporter (SGLT) and glucose transporter (GLUT) expression in the kidney of type 2 diabetic subjects. Diabetes Obes Metab 19 (2017), 1322–1326.
98. Tabatabai, N.M., Sharma, M., Blumenthal, S.S., et al. Enhanced expressions of sodium-glucose cotransporters in the kidneys of diabetic Zucker rats. Diabetes Res Clin Pract 83 (2009), e27–e30.
99. Solini, A., Rossi, C., Mazzanti, C.M., et al. Sodium-glucose co-transporter (SGLT)2 and SGLT1 renal expression in patients with type 2 diabetes. Diabetes Obes Metab 19 (2017), 1289–1294.
100. Barnett, A.H., Mithal, A., Manassie, J., et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2 (2014), 369–384.
101. Cherney, D., Lund, S.S., Perkins, B.A., et al. The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes. Diabetologia 59 (2016), 1860–1870.
102. Cherney, D.Z.I., Zinman, B., Inzucchi, S.E., et al. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 5 (2017), 610–621.
103. Heerspink, H.J., Desai, M., Jardine, M., et al. Canagliflozin slows progression of renal function decline independently of glycemic effects. J Am Soc Nephrol, 2016.
104. Heerspink, H.J., Kropelin, T.F., Hoekman, J., et al. Drug-induced reduction in albuminuria is associated with subsequent renoprotection: a meta-analysis. J Am Soc Nephrol 26 (2015), 2055–2064.
105. Heerspink, H.J., Ninomiya, T., Persson, F., et al. Is a reduction in albuminuria associated with renal and cardiovascular protection? A post hoc analysis of the ALTITUDE trial. Diabetes Obes Metab 18 (2016), 169–177.
106. MacIsaac, R.J., Tsalamandris, C., Panagiotopoulos, S., et al. Nonalbuminuric renal insufficiency in type 2 diabetes. Diabetes Care 27 (2004), 195–200.
107. Ruggenenti, P., Porrini, E.L., Gaspari, F., et al. Glomerular hyperfiltration and renal disease progression in type 2 diabetes. Diabetes Care 35 (2012), 2061–2068.
108. Fitchett, D., Zinman, B., Wanner, C., et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME trial. Eur Heart J 37 (2016), 1526–1534.
109. Rahman, A., Kittikulsuth, W., Fujisawa, Y., et al. Effects of diuretics on sodium-dependent glucose cotransporter 2 inhibitor-induced changes in blood pressure in obese rats suffering from the metabolic syndrome. J Hypertens 34 (2016), 893–906.
110. Weber, M.A., Mansfield, T.A., Cain, V.A., et al. Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Diabetes Endocrinol 4 (2016), 211–220.
111. Johnsson, K., Johnsson, E., Mansfield, T.A., et al. Osmotic diuresis with SGLT2 inhibition: analysis of events related to volume reduction in dapagliflozin clinical trials. Postgrad Med 128 (2016), 346–355.
112. Harper, W., Clement, M., Goldenberg, R., et al. Pharmacologic management of type 2 diabetes. Can J Diabetes 37:suppl 1 (2016), S61–S68.
113. Jabbour, S., Seufert, J., Scheen, A., et al. Dapagliflozin in patients with type 2 diabetes mellitus: a pooled analysis of safety data from phase IIb/III clinical trials. Diabetes Obes Metab 20 (2018), 620–628.
114. Jorsal, A., Kistorp, C., Holmager, P., et al. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail 19 (2017), 69–77.
115. Nauck, M.A., Meier, J.J., GLP-1 receptor agonists and SGLT2 inhibitors: a couple at last?. Lancet Diabetes Endocrinol 4 (2016), 963–964.
116. Frias, J.P., Guja, C., Hardy, E., et al. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol 4 (2016), 1004–1016.
117. Seino, Y., Yabe, D., Sasaki, T., et al. Sodium glucose transporter-2 inhibitor luseogliflozin added to glucagon-like peptide 1 receptor agonist liraglutide improves glycemic control with bodyweight and fat mass reductions in Japanese patients with type 2 diabetes: a 52-week, open-label, single-arm study. J Diabetes Investig 9 (2018), 332–340.
118. Fadini, G.P., Avogaro, A., SGTL2 inhibitors and amputations in the US FDA Adverse Event Reporting System. Lancet Diabetes Endocrinol 5 (2017), 680–681.
119. Fralick, M., Schneeweiss, S., Patorno, E., Risk of Diabetic ketoacidosis after initiation of an SGLT2 inhibitor. N Engl J Med 376 (2017), 2300–2302.
120. Masuta P, Johri G, Paul M. SGLT2 Inhibitors and euglycemic ketoacidosis [e-pub ahead of print]. Am J Ther. https://doi.org/10.1097/MJT.0000000000000587. Accessed March 3, 2018.
121. Jensen, M.L., Persson, F., Andersen, G.S., et al. Incidence of ketoacidosis in the Danish type 2 diabetes population before and after introduction of sodium-glucose cotransporter 2 inhibitors-a nationwide, retrospective cohort study, 1995-2014. Diabetes Care 40 (2017), e57–e58.
122. Inzucchi, S.E., Iliev, H., Pfarr, E., et al. Empagliflozin and assessment of lower-limb amputations in the EMPA-REG OUTCOME trial. Diabetes Care 41 (2018), e4–e5.e1.
123. Verma, S., Mazer, C.D., Al-Omran, M., et al. Cardiovascular outcomes and safety of empagliflozin in patients with type 2 diabetes mellitus and peripheral artery disease: a subanalysis of EMPA-REG OUTCOME. Circulation 137 (2018), 405–407.
124. Udell JA, Yuan Z, Rush T, et al. Cardiovascular outcomes and risks after initiation of a sodium glucose co-transporter 2 inhibitor: results from the EASEL Population-Based Cohort Study [e-pub ahead of print]. Circulation. https://doi.org/10.1161/CIRCULATIONAHA.117.031227.
125. Yuan, Z., DeFalco, F.J., Ryan, P.B., et al. Risk of lower extremity amputations in patients with type 2 diabetes mellitus treated with sglt2 inhibitors in the United States: a retrospective cohort study. Diabetes Obes Metab 20 (2018), 582–589.
126. Erkens, J.A., Klungel, O.H., Stolk, R.P., et al. Antihypertensive drug therapy and the risk of lower extremity amputations in pharmacologically treated type 2 diabetes patients. Pharmacoepidemiol Drug Saf 13 (2004), 139–146.
127. Hawley, S.A., Ford, R.J., Smith, B.K., et al. The Na+/glucose cotransporter inhibitor canagliflozin activates AMPK by inhibiting mitochondrial function and increasing cellular AMP levels. Diabetes 65 (2016), 2784–2794.
128. Ruanpeng, D., Ungprasert, P., Sangtian, J., et al. Sodium-glucose cotransporter 2 (SGLT2) inhibitors and fracture risk in patients with type 2 diabetes mellitus: a meta-analysis. Diabetes Metab Res Rev, 33(6), 2017 https://doi.org/10.1002/dmrr.2903.
129. Blevins, T.C., Farooki, A., Bone effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus. Postgrad Med 129 (2017), 159–168.
130. Alba, M., Xie, J., Fung, A., et al. The effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on mineral metabolism and bone in patients with type 2 diabetes mellitus. Curr Med Res Opin 32 (2016), 1375–1385.
131. Weir, M.R., Kline, I., Xie, J., et al. Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR). Curr Med Res Opin 30 (2014), 1759–1768.
132. Tang, H., Zhang, X., Zhang, J., et al. Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients: a meta-analysis of randomised controlled trials. Diabetologia 59 (2016), 2546–2551.
133. Ahmadieh, H., Azar, S., Effects of sodium glucose cotransporter-2 inhibitors on serum uric acid in type 2 diabetes mellitus. Diabetes Technol Ther 19 (2017), 507–512.
134. Chino, Y., Samukawa, Y., Sakai, S., et al. SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria. Biopharm Drug Dispos 35 (2014), 391–404.
135. Zhao, Y., Xu, L., Tian, D., et al. Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: a meta-analysis of randomized controlled trials. Diabetes Obes Metab 20 (2018), 458–462.
136. Nadkarni, G.N., Ferrandino, R., Chang, A., et al. Acute kidney injury in patients on SGLT2 inhibitors: a propensity-matched analysis. Diabetes Care 40 (2017), 1479–1485.
137. Heyman, S.N., Khamaisi, M., Rosen, S., et al. Potential hypoxic renal injury in patients with diabetes on SGLT2 inhibitors: caution regarding concomitant use of NSAIDs and iodinated contrast media. Diabetes Care 40 (2017), e40–e41.
138. Pecoits-Filho, R., Perkovic, V., Are SGLT2 inhibitors ready for prime time for CKD?. Clin J Am Soc Nephrol 13 (2018), 318–320.
139. Perico, N., Benigni, A., Gabanelli, M., et al. Atrial natriuretic peptide and prostacyclin synergistically mediate hyperfiltration and hyperperfusion of diabetic rats. Diabetes 41 (1992), 533–538.
140. DeFronzo, R.A., Lewin, A., Patel, S., et al. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. Diabetes Care 38 (2015), 384–393.